Join us for a Pink Ribbon Walk this spring Choose from 4 incredible walks, each in an iconic destination surrounded by spectacular scenery. 10 or 20 mile options are available.
Book a Public Health Talk Raise awareness of breast cancer in your local community or network by booking a free online or in-person talk.
Home About us Media Breast Cancer Now media statements 193 results We respond to the launch of the first UK proton beam therapy trial for breast cancer patients 03 Jan 2023 1 min read We respond to new estimates that 57,215 people were living with secondary (metastatic) breast cancer in England in 2020 to 2021 22 Dec 2022 2 min read We respond to NICE’s approval of trastuzumab deruxtecan (Enhertu) for use on the Cancer Drugs Fund 20 Dec 2022 1 min read We respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant 12 Dec 2022 2 min read We respond to research about a potential new treatment for advanced breast cancer patients 08 Dec 2022 1 min read We respond to research about the benefits of exercise 18 Nov 2022 1 min read We respond to research about radiotherapy and long-term breast cancer survival 18 Nov 2022 1 min read We respond to research about women with benign breast disease being at higher risk of breast cancer in the long term 17 Nov 2022 1 min read We respond to latest NHSE Cancer Wait Times data 11 Nov 2022 1 min read We respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS 10 Nov 2022 2 min read Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95% 13 Oct 2022 1 min read Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland 10 Oct 2022 1 min read Previous 1 ... 8 ... 17 Next
We respond to the launch of the first UK proton beam therapy trial for breast cancer patients 03 Jan 2023 1 min read
We respond to new estimates that 57,215 people were living with secondary (metastatic) breast cancer in England in 2020 to 2021 22 Dec 2022 2 min read
We respond to NICE’s approval of trastuzumab deruxtecan (Enhertu) for use on the Cancer Drugs Fund 20 Dec 2022 1 min read
We respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant 12 Dec 2022 2 min read
We respond to research about a potential new treatment for advanced breast cancer patients 08 Dec 2022 1 min read
We respond to research about radiotherapy and long-term breast cancer survival 18 Nov 2022 1 min read
We respond to research about women with benign breast disease being at higher risk of breast cancer in the long term 17 Nov 2022 1 min read
We respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS 10 Nov 2022 2 min read
Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95% 13 Oct 2022 1 min read
Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland 10 Oct 2022 1 min read
